Key Details
Price
$10.82Annual ROE
-29.98%Beta
1.65Events Calendar
Next earnings date:
Mar 04, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 04, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Aug 20, 2021Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We had another strong quarter of execution for both navenibart and STAR-0310,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We are excited about the opportunity for navenibar.
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024. Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and.
Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito - Chief Medical Officer Andrea Matthews - Chief Business Officer Andrew Komjathy - Chief Commercial Officer Conference Call Participants Eun Yang - Jefferies Sam Slutsky - LifeSci Capital Hartaj Singh - Oppenheimer Farhana Sakloth - Ladenburg Joe Pantginis - H.C. Wainwright Operator Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update.
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the Unive.
Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of the lead candidate, STAR-0310, a monoclonal antibody OX40 antagonist utilizing YTE half-life extension technology.
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.
Astria: Biotech To Watch With Proof Of Concept Established For HAE.
FAQ
- What is the primary business of Astria Therapeutics?
- What is the ticker symbol for Astria Therapeutics?
- Does Astria Therapeutics pay dividends?
- What sector is Astria Therapeutics in?
- What industry is Astria Therapeutics in?
- What country is Astria Therapeutics based in?
- When did Astria Therapeutics go public?
- Is Astria Therapeutics in the S&P 500?
- Is Astria Therapeutics in the NASDAQ 100?
- Is Astria Therapeutics in the Dow Jones?
- When was Astria Therapeutics's last earnings report?
- When does Astria Therapeutics report earnings?
- Should I buy Astria Therapeutics stock now?